Physician profile
Gregory Headley
NPI 1013424886
$11,232.49
in general payments reported to CMS, 2019-2025
46 companies · $2,484 in 2025
The $2,484 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,404 · 2022: $1,838 · 2023: $1,888 · 2024: $2,618 · 2025: $2,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,990.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,636.46 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,110.22 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,085.88 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $894.79 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $690.70 | 2021-2025 | Trintellix |
| Pfizer INC. | $550.99 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $534.03 | 2023-2025 | Caplyta |
| Antares Pharma, INC. | $490.73 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Amgen INC. | $363.95 | 2021-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $348.11 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.67 | 2021-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $296.37 | 2023-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $269.02 | 2021-2025 | |
| Lundbeck LLC | $267.41 | 2022-2025 | Vyepti, Rexulti |
| Amarin Pharma, INC. | $240.42 | 2021-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $197.00 | 2021-2022 | |
| Clarus Therapeutics INC. | $194.94 | 2021 | |
| Sanofi-Aventis U.S. LLC | $160.68 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $154.54 | 2022-2025 | Rexulti |
| Ardelyx, INC. | $152.72 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $145.30 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $144.24 | 2021-2025 | Spravato |
| Corcept Therapeutics | $88.80 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $82.03 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $76.19 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $70.68 | 2022-2025 | Austedo Xr |
| Merck Sharp & Dohme LLC | $66.93 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Arbor Pharmaceuticals, INC. | $57.70 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $57.18 | 2021 | |
| Abbott Laboratories | $54.87 | 2021-2024 | Proclaim, Freestyle Libre 3 |
| Indivior INC. | $52.24 | 2024-2025 | Sublocade |
| Astellas Pharma US INC | $48.67 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.24 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $37.02 | 2021-2022 | |
| Halozyme INC | $33.27 | 2023 | |
| Axsome Therapeutics, INC. | $31.14 | 2023-2024 | Auvelity |
| Sanofi Pasteur INC. | $28.54 | 2025 | |
| Idorsia Pharmaceuticals US INC | $27.57 | 2023 | Quviviq |
| Inspire Medical Systems, INC. | $24.75 | 2025 | Inspire |
| Tolmar, INC. | $22.70 | 2025 | Jatenzo |
| Xeris Pharmaceuticals, INC. | $22.27 | 2025 | Keveyis |
| Sumitomo Pharma America, INC. | $20.94 | 2024 | Gemtesa |
| Dexcom, INC. | $20.00 | 2025 | Dexcom G6 Transmitter |
| Scynexis, INC. | $17.28 | 2022 | |
| Supernus Pharmaceuticals, INC. | $11.27 | 2021 | Xyosted, Tlando |
| Adlon Therapeutics L.P. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Headley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.